Loading the records…
Loading the records…
The HELP Copays Act (S.864) would require group health plans to count financial assistance from drug manufacturers and non-profits toward patient deductible and out-of-pocket limits. The bill is in committee with 26 cosponsors and a companion House bill. If enacted, it would benefit pharmaceutical companies by boosting drug utilization, while insurers face higher claims costs. No market data is provided, but structural impacts are clear.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The HELP Copays Act directly impacts healthcare sector dynamics. Pharmaceutical companies with strong branded drug portfolios (LLY, MRK, PFE, ABBV, JNJ) could see modest revenue gains if the bill passes, due to improved effectiveness of copay cards. Insurers like UNH may face higher medical costs but the impact is small relative to their scale. No market price data is available, but the structural bias is positive for pharma and slightly negative for insurers.
The HELP Copays Act (S.864) was introduced on March 5, 2025 by Sen. Roger Marshall (R-KS) and has 26 cosponsors including both parties. Hearings were held in the Senate HELP Committee on March 19, 2026. The bill amends the Public Health Service Act to require that amounts paid by or on behalf of individuals—including financial assistance from non-profit organizations and prescription drug manufacturers—count toward the deductible, coinsurance, copayment, and out-of-pocket limit. A companion bill (HR6423) has been introduced in the House. The bill is still in committee and has not passed either chamber.
The legislation involves no direct government funding; it is a regulatory mandate on private health insurance plans. The money trail runs through insurance claims: by counting manufacturer copay assistance toward out-of-pocket limits, patients will hit their deductibles and maximums faster, increasing insurer liability for drug costs. Pharmaceutical companies benefit because patients are more likely to fill prescriptions when copay assistance is effective, boosting sales volume.
No convergence signals are present in the provided data. The bill stands alone as a targeted health policy initiative.
Structural winners are pharmaceutical companies with high-priced branded drugs that use copay assistance programs: $LLY (revenue $34.1B), $MRK ($60.1B), $PFE ($59.6B), $ABBV ($54.3B), ($85.2B). For these, the bill enhances their existing patient assistance programs, potentially increasing net revenue by 1-3% depending on drug mix. Structural losers are health insurers: (revenue $371.6B) faces higher drug claim costs, though its Optum PBM may offset some impact through formulary adjustments. The net effect on UNH is bearish but moderate given its diversified business.
Timeline: The bill has advanced from introduction to hearings, indicating active committee work. However, it has not yet passed the Senate. The next steps are committee markup and then a floor vote. The companion House bill adds momentum but passage this Congress is uncertain. Legislative velocity is moderate.
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →